COVID-19 Update 
Where patients, partners, and quality matter
For over 75 years, Lannett has been proudly providing high-quality, affordable generic pharmaceutical products to patients who depend on them.
What product are you looking for?
Patient Support
We manufacture over 100 unique pharmaceutical product families for a wide range of therapeutic areas, with many more in development. Our philosophy? Patients first.
Our Approach
Many of our patients will never know they are taking one of our medicines. But we know. That’s why we strive for the highest quality standards in our pharmaceutical products.
Careers
Our culture combines a legacy of quality with an appetite for innovation. We’re looking for motivated, engaged individuals to help make the medicines that save and enhance lives.
Spotlight
June 1, 2021
Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing
“The FDA’s Acceptance of the ANDA submission of generic ADVAIR DISKUS® brings us one step closer to providing asthma patients an affordable option for this critical medication,” said Tim Crew, chief executive officer of Lannett. “We anticipate more than one FDA review cycle of this opportunity given the inherent complexity associated with a drug/device combination inhalation product. However, our partners at Respirent have assembled a comprehensive application and have expertise in developing and manufacturing dry powder inhalation products, so we believe we are positioned for a potential U.S. launch of the product in calendar 2022.”